title: Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report.
abstract: In this short paper, we report our experience with eribulin mesylate in a heavily pretreated breast cancer patient with multiple bone metastases. The patient had been treated with doxorubicin, cyclophosphamide, methotrexate, fluorouracil, tamoxifen, letrozole, LH-RH analogs, fulvestrant, bevacizumab and paclitaxel and liposomal doxorubicin. In November 2013 treatment with eribulin ready to use solution (1.23 mg/m(2) days 1 and 8 of a 21-day cycle) was started and administered for a total of 14 courses. After six cycles of eribulin, evaluation with MRI showed a marked decrease in neoplastic involvement and replacement of osteolytic lesions with osteoblastic ones. No unexpected acute toxicity was observed. Although with all the limitations of any anecdotal report, our experience documents the efficacy and safety of eribulin in this difficult-to-treat patient who had been treated with multiple lines of chemotherapy.
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Luigi
authors.initials: L
authors.lastname: Leo
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Caputo
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Antonella Di
authors.initials: AD
authors.lastname: Sarno
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Tiziana
authors.initials: T
authors.lastname: Garofano
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Andreozzi
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Massaro
authors.affiliation: Oncology Unit, Azienda Ospedaliera dei Colli, Naples, Italy.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Montesarchio
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005663:Furans / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007659:Ketones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D019233:Retreatment; D016896:Treatment Outcome; D000095662:Polyether Polyketides
chemical_list: D000970:Antineoplastic Agents; D005663:Furans; D007659:Ketones; C490954:eribulin; D000095662:Polyether Polyketides
keywords: breast cancer; eribulin; safety